Thoratec boosts sales, but profits stay flat

Thanks to its banner HeartMate device, Thoratec ($THOR) handed in another quarter of solid revenue growth, but a spike in costs kept its net income from moving upward. Sales jumped 7% to $125.7 million on the quarter, with HeartMate accounting for $110 million of that figure. Despite the gains, Thoratec's profits came in at $18.2 million, exactly aligned with the first quarter of 2013. Results

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.